Zydus Lifesciences trades lower despite launching two generic drugs for pets; check details

Zydus Lifesciences share price: Shares of Zydus Lifesciences were trading lower on the National Stock Exchange (NSE) on Tuesday, September 16, despite the company’s step-down subsidiary launching two products a day prior.

While the stock was trading in the positive territory during the morning’s session, at the time of writing, it was trading 0.04% lower at ₹1,036.50 per equity share.

In a regulatory filing on Monday, the drug maker announced that ZyVet Animal Health released the first FDA-approved phenylpropanolamine hydrochloride tablets, a treatment for managing urinary incontinence in dogs. It also launched the generic form of Furosemide tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.

Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and ageing dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents, the filing stated.

Commenting on the launch of the urine incontinence treatment drug, Punit Patel, President and CEO of Zydus Americas, said: “Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance. We’re proud to offer an option that removes cost as a barrier to compassionate care.”

Zydus launches generic congestive heart failure treatment drug for pets

ZyVet Animal Health also announced the launch of the first veterinary-approved generic of Furosemide Tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.

Furosemide remains the most widely used veterinary diuretic for reducing edema and pulmonary congestion due to cardiac, renal, or systemic disease. ZyVet’s formulation offers veterinarians a consistent, cost-effective solution that supports long-term therapy, without compromising dosing flexibility or product availability, the filing stated.

Both the newly released tablets, designed for the needs of both veterinary teams and pet owners, will be available in various strengths for precise dosing.

ZyVet Animal Health, a leader in affordable generic pharmaceuticals for animals, is a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences Ltd.

While the share reached a year’s low of ₹795 on April 7, 2025, it touched a 52-week high of ₹1,133 apiece a year ago on September 16, 2024.

Zydus Lifesciences has a total market capitalisation of ₹1.04 lakh crore, as of September 16, 2025, according to data on the NSE.